首页> 外文期刊>Molecular cancer research: MCR >Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
【24h】

Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.

机译:肿瘤坏死因子相关凋亡诱导配体受体1(DR4)的表观遗传沉默对TRAIL耐药性和卵巢癌的贡献。

获取原文
获取原文并翻译 | 示例
           

摘要

Dysregulation of apoptosis may support tumorigenesis by allowing cells to live beyond their normally intended life span. The various receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) are located on chromosome 8p21.2, a region frequently deleted in ovarian cancer. Lack of expression of TRAIL receptor 1 (death receptor 4, DR4) correlates with resistance to TRAIL-induced apoptosis in ovarian cancer cells. Reconstitution of DR4 in the TRAIL-resistant A2780 ovarian cancer cell line was investigated with the demethylating agent 5-aza-2'-deoxycytidine and transient gene transfer. Regulation of other genes in the TRAIL pathway by 5-aza-2'-deoxycytidine was assessed in DNA GeneChip experiments. Primary ovarian cancers were analyzed by methylation-specific PCR and immunohistochemical analysis of a tissue microarray. Regulation of DR4 expression by demethylation or transient transfection is of functional relevance for TRAIL resistance in an ovarian cancer cell line. Hypermethylation ofthe DR4 promoter could be found in 10 of 36 (27.7%) DNAs isolated from ovarian cancer tissue. In an independent set of 68 ovarian cancer cases, a complete loss or down-regulation of DR4 protein expression was observed 10.3% and 8.8% patients, respectively. A significant (P = 0.019) majority of these patients was below 50 years of age. Our findings show a functional relevance of the level of DR4 expression in ovarian cancer and suggest a substantial contribution of DR4 hypermethylation and consequent loss of DR4 expression to ovarian cancer pathogenesis, particularly in premenopausal patients.
机译:细胞凋亡的失调可通过允许细胞存活超过其正常预期寿命来支持肿瘤发生。肿瘤坏死因子相关的凋亡诱导配体(TRAIL)的各种受体位于染色体8p21.2,这是卵巢癌中经常删除的区域。 TRAIL受体1(死亡受体4,DR4)表达的缺乏与卵巢癌细胞对TRAIL诱导的凋亡的抵抗有关。用去甲基化剂5-氮杂-2'-脱氧胞苷和瞬时基因转移研究了TRAIL耐药A2780卵巢癌细胞系中DR4的重建。在DNA GeneChip实验中评估了5-氮杂2'-脱氧胞苷对TRAIL途径中其他基因的调控。通过甲基化特异性PCR和组织芯片的免疫组织化学分析来分析原发性卵巢癌。通过脱甲基或瞬时转染来调节DR4表达与卵巢癌细胞系中TRAIL抗性具有功能相关性。在从卵巢癌组织中分离出的36个DNA中,有10个(27.7%)发现了DR4启动子的超甲基化。在一组独立的68例卵巢癌病例中,分别观察到DR4蛋白表达完全丧失或下调的患者分别为10.3%和8.8%。这些患者中有很大一部分(P = 0.019)低于50岁。我们的发现显示卵巢癌中DR4表达水平的功能相关性,并提示DR4高度甲基化以及由此引起的DR4表达丧失对卵巢癌发病机理的重大贡献,尤其是在绝经前患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号